CoChat

TAK‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia

Open access
Ghobrial, Irene M., Siegel, David S., Vij, Ravi, Berdeja, Jesus G., Richardson, Paul G., Neuwirth, Rachel, Patel, Chirag G., Zohren, Fabian, Wolf, Jeffrey L. · 2016 · American Journal of Hematology
Cited by 95

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non‐Hodgkin lymphoma (NHL), and Waldenström's macroglobulinemia (WM). This was the first clinical study to evaluate the safety, tolerability, maximal‐tolerated dose (MTD), dose‐limiting toxicity (DLT), pharmacokinetics, and preliminary clinical activity of TAK‐228, an oral TORC1/2 inhibitor, in patients with MM, NHL, or WM. Thirty‐nine patients received TAK‐228 once daily (QD) at 2, 4, 6, or 7 mg, or QD for 3 days on and 4 days off each week (QDx3d QW) at 9 or 12 mg, in 28‐day cycles. The overall median age was 61.0 years (range 46–85); 31 patients had MM, four NHL, and four WM. Cycle 1 DLTs occurred in five QD patients (stomatitis, urticaria, blood creatinine elevation, fatigue, and nausea and vomiting) and four QDx3d QW patients (erythematous rash, fatigue, asthenia, mucosal inflammation, and thrombocytopenia). The MTDs were determined to be 4 mg QD and 9 mg QDx3d QW. Thirty‐six patients (92%) reported at least one drug‐related toxicity; the most common grade ≥3 drug‐related toxicities were thrombocytopenia (15%), fatigue (10%), and neutropenia (5%). TAK‐228 exhibited a dose‐dependent increase in plasma exposure and no appreciable accumulation with repeat dosing; mean plasma elimination half‐life was 6–8 hr. Of the 33 response‐evaluable patients, one MM patient had a minimal response, one WM patient achieved partial response, one WM patient had a minor response, and 18 patients (14 MM, two NHL, and two WM) had stable disease. These findings encourage further studies including combination strategies. Am. J. Hematol. 91:400–405, 2016. © 2016 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.24300

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 95

Metadata

Authors
Ghobrial, I. M., Siegel, D. S., Vij, R., Berdeja, J. G., Richardson, P. G., Neuwirth, R., Patel, C. G., Zohren, F., & Wolf, J. L.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2016-03-18
Volume
91
Issue
4
Pages
400-405
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W2286842342
Cited by
95
References
11
FWCI
6.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TAK‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia. https://app.cochat.ai/papers/10.1002/ajh.24300
The paper
Ghobrial, I. M., Siegel, D. S., Vij, R., Berdeja, J. G., Richardson, P. G., Neuwirth, R., Patel, C. G., Zohren, F., & Wolf, J. L. (2016). TAK‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia. American Journal of Hematology. https://doi.org/10.1002/ajh.24300

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.